The antineoplastic properties of FTY720: Evidence for the repurposing of fingolimod

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 10, 2015, Pages 2329-2340

  Patmanathan, Sathya Narayanan ^a   Yap, Lee Fah ^a   Murray, Paul G ^b   Paterson, Ian C ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Apoptosis; Cancer; Cytotoxicity; Fingolimod; FTY720; S1P; Sphingosine analogue

Indexed keywords

FINGOLIMOD; LIPOSOME; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE 1; SURVIVIN; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CARCINOGENESIS; CELL DEATH; CELL MOTILITY; CELL PROLIFERATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GROWTH INHIBITION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; METASTASIS; MULTIPLE SCLEROSIS; PHENOTYPE; PHOSPHORYLATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPHINGOLIPID METABOLISM; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG REPOSITIONING; HUMAN;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG REPOSITIONING; FINGOLIMOD HYDROCHLORIDE; HUMANS; PHENOTYPE; SIGNAL TRANSDUCTION;

EID: 84942314194     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12635     Document Type: Article

References (111)

1. Fujita T, Inoue K, Yamamoto S, et al. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot. 1994; 47: 208-15.
2. Strader CR, Pearce CJ, Oberlies NH. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite. J Nat Prod. 2011; 74: 900-7.
3. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010; 33: 91-101.
4. Adada M, Canals D, Hannun YA, et al. Sphingosine-1-phosphate receptor 2. FEBS J. 2013; 280: 6354-66.
5. Ponnusamy S, Meyers-Needham M, Senkal CE, et al. Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncol. 2010; 6: 1603-24.
6. Pyne S, Pyne NJ. New perspectives on the role of sphingosine 1-phosphate in cancer. Handb Exp Pharmacol. 2013; 216. Doi: 10.1007/978-3-7091-1511-4_3:55-71.
7. Pitman MR, Woodcock JM, Lopez AF, et al. Molecular targets of FTY720 (fingolimod). Curr Mol Med. 2012; 12: 1207-19.
8. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002; 277: 21453-7.
9. Mehling M, Johnson TA, Antel J, et al. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology. 2011; 76: S20-7.
10. Liang J, Nagahashi M, Kim EY, et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell. 2013; 23: 107-20.
11. Chiba K, Matsuyuki H, Maeda Y, et al. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus. Cell Mol Immunol. 2006; 3: 11-9.
12. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010; 9: 883-97.
13. Lee JW, Ryu JY, Yoon G, et al. Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer. Int J Cancer. 2014; 137. Doi: 10.1002/ijc.29362.
14. Rosa R, Marciano R, Malapelle U, et al. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clin Cancer Res. 2013; 19: 138-47.
15. Tonelli F, Lim KG, Loveridge C, et al. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell Signal. 2010; 22: 1536-42.
16. Lim KG, Tonelli F, Berdyshev E, et al. Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: functional differences between sphingosine kinase 1a and 1b. Int J Biochem Cell Biol. 2012; 44: 1457-64.
17. Li MH, Hla T, Ferrer F. FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway. Pediatr Blood Cancer. 2013; 60: 1418-23.
18. Kim HJ, Qiao Q, Toop HD, et al. A fluorescent assay for ceramide synthase activity. J Lipid Res. 2012; 53: 1701-7.
19. Lahiri S, Park H, Laviad EL, et al. Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner. J Biol Chem. 2009; 284: 16090-8.
20. Bandhuvula P, Tam YY, Oskouian B, et al. The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity. J Biol Chem. 2005; 280: 33697-700.
21. Liao A, Broeg K, Fox T, et al. Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood. 2011; 118: 2793-800.
22. Pchejetski D, Bohler T, Brizuela L, et al. FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res. 2010; 70: 8651-61.
23. Chen W, Wang Z, Jiang C, et al. PP2A-mediated anticancer therapy. Gastroenterol Res Pract. 2013; 2013: 675429.
24. Walter G, Ruediger R. Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways. Cell Cycle. 2012; 11: 451-9.
25. Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem. 1996; 271: 11059-62.
26. Pippa R, Dominguez A, Christensen DJ, et al. Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity. Leukemia. 2014; 28: 1915-8.
27. Yang Y, Huang Q, Lu Y, et al. Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation. J Cell Biochem. 2012; 113: 1314-22.
28. Oaks JJ, Santhanam R, Walker CJ, et al. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 2013; 122: 1923-34.
29. Saddoughi SA, Gencer S, Peterson YK, et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med. 2013; 5: 105-21.
30. Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res. 2009; 102: 19-65.
31. Cristobal I, Manso R, Rincon R, et al. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Mol Cancer Ther. 2014; 13: 938-47.
32. + cancers. Cancer Res. 2010; 70: 5438-47.
33. Kiyota M, Kuroda J, Yamamoto-Sugitani M, et al. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors. Apoptosis. 2013; 18: 1437-46.
34. Hung JH, Lu YS, Wang YC, et al. FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. Cancer Res. 2008; 68: 1204-12.
35. Lee TK, Man K, Ho JW, et al. FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis. 2004; 25: 2397-405.
36. Zheng T, Meng X, Wang J, et al. PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice. J Cell Biochem. 2010; 111: 218-28.
37. Cristobal I, Garcia-Orti L, Cirauqui C, et al. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia. 2011; 25: 606-14.
38. Liu Q, Zhao X, Frissora F, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood. 2008; 111: 275-84.
39. Neviani P, Santhanam R, Oaks JJ, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007; 117: 2408-21.
40. Dar A, Wu D, Lee N, et al. 14-3-3 proteins play a role in the cell cycle by shielding cdt2 from ubiquitin-mediated degradation. Mol Cell Biol. 2014; 34: 4049-61.
41. Masters SC, Fu H. 14-3-3 proteins mediate an essential anti-apoptotic signal. J Biol Chem. 2001; 276: 45193-200.
42. Woodcock JM, Ma Y, Coolen C, et al. Sphingosine and FTY720 directly bind pro-survival 14-3-3 proteins to regulate their function. Cell Signal. 2010; 22: 1291-9.
43. Nogueira V, Hay N. Molecular pathways: reactive oxygen species homeostasis in cancer cells and implications for cancer therapy. Clin Cancer Res. 2013; 19: 4309-14.
44. Alinari L, Mahoney E, Patton J, et al. FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. Blood. 2011; 118: 6893-903.
45. Pereira FV, Arruda DC, Figueiredo CR, et al. FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system. Clinics. 2013; 68: 1018-27.
46. Wallington-Beddoe CT, Hewson J, Bradstock KF, et al. FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells. Autophagy. 2011; 7: 707-15.
47. Liu Q, Alinari L, Chen CS, et al. FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res. 2010; 16: 3182-92.
48. Zhang N, Qi Y, Wadham C, et al. FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy. Autophagy. 2010; 6: 1157-67.
49. Xing Y, Wang ZH, Ma DH, et al. FTY720 enhances chemosensitivity of colon cancer cells to doxorubicin and etoposide via the modulation of P-glycoprotein and multidrug resistance protein 1. J Dig Dis. 2014; 15: 246-59.
50. Nagaoka Y, Otsuki K, Fujita T, et al. Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells. Biol Pharm Bull. 2008; 31: 1177-81.
51. Azuma H, Horie S, Muto S, et al. Selective cancer cell apoptosis induced by FTY720; evidence for a Bcl-dependent pathway and impairment in ERK activity. Anticancer Res. 2003; 23: 3183-93.
52. Azuma H, Takahara S, Ichimaru N, et al. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res. 2002; 62: 1410-9.
53. Zhou C, Ling MT, Kin-Wah Lee T, et al. FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase. Cancer Lett. 2006; 233: 36-47.
54. Liu Y, Deng J, Wang L, et al. S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma. Blood. 2012; 120: 1458-65.
55. Yasui H, Hideshima T, Raje N, et al. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res. 2005; 65: 7478-84.
56. Shah MV, Zhang R, Irby R, et al. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood. 2008; 112: 770-81.
57. Zhang L, Wang HD, Ji XJ, et al. FTY720 for cancer therapy. Oncol Rep. 2013; 30: 2571-8.
58. Neviani P, Harb JG, Oaks JJ, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest. 2013; 123: 4144-57.
59. Romero Rosales K, Singh G, Wu K, et al. Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins. Biochem J. 2011; 439: 299-311.
60. Ubai T, Azuma H, Kotake Y, et al. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft. Anticancer Res. 2007; 27: 75-88.
61. Ho JW, Man K, Sun CK, et al. Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol Cancer Ther. 2005; 4: 1430-8.
62. Tay KH, Liu X, Chi M, et al. Involvement of vacuolar H -ATPase in killing of human melanoma cells by the sphingosine kinase analogue FTY720. Pigment Cell Melanoma Res. 2014; 28. Doi: 10.1111/pcmr.12326.
63. Chua CW, Lee DT, Ling MT, et al. FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int J Cancer. 2005; 117: 1039-48.
64. Azuma H, Takahara S, Horie S, et al. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol. 2003; 169: 2372-7.
65. Lu Z, Wang J, Zheng T, et al. FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling. BMC Cancer. 2014; 14: 783.
66. Lee YS, Nakajima H, Tsuruga M, et al. Elimination of cell-cycle regulators during caspase-3-dependent apoptosis caused by an immunosuppressant, FTY720. Biosci Biotechnol Biochem. 2003; 67: 467-74.
67. Permpongkosol S, Wang JD, Takahara S, et al. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. Int J Cancer. 2002; 98: 167-72.
68. Liao A, Hu R, Zhao Q, et al. Autophagy induced by FTY720 promotes apoptosis in U266 cells. Eur J Pharm Sci. 2012; 45: 600-5.
69. Estrada-Bernal A, Palanichamy K, Ray Chaudhury A, et al. Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma. Neuro Oncol. 2012; 14: 405-15.
70. + cancers - Letter. Cancer Res. 2011; 71: 2403.
71. Marvaso G, Barone A, Amodio N, et al. Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro. Cancer Biol Ther. 2014; 15: 797-805.
72. Huang X, Taeb S, Jahangiri S, et al. miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. Cancer Res. 2013; 73: 6972-86.
73. Nagahara Y, Matsuoka Y, Saito K, et al. Coordinate involvement of cell cycle arrest and apoptosis strengthen the effect of FTY720. Jpn J Cancer Res. 2001; 92: 680-7.
74. Kenific CM, Debnath J. Cellular and metabolic functions for autophagy in cancer cells. Trends Cell Biol. 2015; 25: 37-45.
75. Zhang L, Wang H, Zhu J, et al. FTY720 reduces migration and invasion of human glioblastoma cell lines via inhibiting the PI3K/AKT/mTOR/p70S6K signaling pathway. Tumour Biol. 2014; 35: 10707-14.
76. Chua CW, Chiu YT, Yuen HF, et al. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform. Clin Cancer Res. 2009; 15: 4322-35.
77. Ushitora Y, Tashiro H, Ogawa T, et al. Suppression of hepatocellular carcinoma recurrence after rat liver transplantation by FTY720, a sphingosine-1-phosphate analog. Transplantation. 2009; 88: 980-6.
78. Lee TK, Man K, Ho JW, et al. Significance of the Rac signaling pathway in HCC cell motility: implications for a new therapeutic target. Carcinogenesis. 2005; 26: 681-7.
79. Lee TK, Man K, Ho JW, et al. FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res. 2005; 11: 8458-66.
80. Shen Y, Cai M, Xia W, et al. FTY720, a synthetic compound from Isaria sinclairii, inhibits proliferation and induces apoptosis in pancreatic cancer cells. Cancer Lett. 2007; 254: 288-97.
81. LaMontagne K, Littlewood-Evans A, Schnell C, et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res. 2006; 66: 221-31.
82. Kluk MJ, Ryan KP, Wang B, et al. Sphingosine-1-phosphate receptor 1 in classical Hodgkin lymphoma: assessment of expression and role in cell migration. Lab Invest. 2013; 93: 462-71.
83. Murali A, Rajalingam K. Small Rho GTPases in the control of cell shape and mobility. Cell Mol Life Sci. 2014; 71: 1703-21.
84. Steinestel K, Eder S, Schrader AJ, et al. Clinical significance of epithelial-mesenchymal transition. Clin Transl Med. 2014; 3: 17.
85. Liu H, Gu Y, Yin J, et al. SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell. Cell Signal. 2014; 26: 2710-20.
86. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003; 3: 401-10.
87. Schmid G, Guba M, Ischenko I, et al. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. J Cell Biochem. 2007; 101: 259-70.
88. Mousseau Y, Mollard S, Faucher-Durand K, et al. Fingolimod potentiates the effects of sunitinib malate in a rat breast cancer model. Breast Cancer Res Treat. 2012; 134: 31-40.
89. McGee MC, Hamner JB, Williams RF, et al. Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys. 2010; 76: 1537-45.
90. Huang G, Chen L. Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol. 2010; 136: 1201-11.
91. Soleimani R, Heytens E, Oktay K. Enhancement of neoangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants. PLoS ONE. 2011; 6: e19475.
92. Li CX, Shao Y, Ng KT, et al. FTY720 suppresses liver tumor metastasis by reducing the population of circulating endothelial progenitor cells. PLoS ONE. 2012; 7: e32380.
93. Diakos CI, Charles KA, McMillan DC, et al. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014; 15: e493-503.
94. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-74.
95. Conzett KB, Kolm I, Jelcic I, et al. Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report. Arch Dermatol. 2011; 147: 991-2.
96. Ingwersen J, Aktas O, Kuery P, et al. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. Clin Immunol. 2012; 142: 15-24.
97. Lorvik KB, Bogen B, Corthay A. Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice. Blood. 2012; 119: 2176-7.
98. Omar HA, Chou CC, Berman-Booty LD, et al. Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology. 2011; 53: 1943-58.
99. Mani R, Mao Y, Frissora FW, et al. Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia. Leukemia. 2015; 29: 346-55.
100. Fransson R, McCracken AN, Chen B, et al. Design, synthesis, and anti-leukemic activity of stereochemically defined constrained analogs of FTY720 (Gilenya). ACS Med Chem Lett. 2013; 4: 969-73.
101. Tonelli F, Alossaimi M, Natarajan V, et al. The roles of sphingosine kinase 1 and 2 in regulating the metabolome and survival of prostate cancer cells. Biomolecules. 2013; 3: 316-33.
102. Tonelli F, Alossaimi M, Williamson L, et al. The sphingosine kinase inhibitor 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress-dependent mechanism. Br J Pharmacol. 2013; 168: 1497-505.
103. Lim KG, Tonelli F, Li Z, et al. FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells. J Biol Chem. 2011; 286: 18633-40.
104. Knott K, Kharel Y, Raje MR, et al. Effect of alkyl chain length on sphingosine kinase 2 selectivity. Bioorg Med Chem Lett. 2012; 22: 6817-20.
105. Lim KG, Sun C, Bittman R, et al. (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells. Cell Signal. 2011; 23: 1590-5.
106. Watson DG, Tonelli F, Alossaimi M, et al. The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells. Cell Signal. 2013; 25: 1011-7.
107. Mao Y, Wang J, Zhao Y, et al. A novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery. Nanomedicine. 2014; 10: 393-400.
108. Yu B, Mao Y, Yuan Y, et al. Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells. Biomaterials. 2013; 34: 6185-93.
109. Pantziarka P, Bouche G, Meheus L, et al. Repurposing drugs in your medicine cabinet: untapped opportunities for cancer therapy? Future Oncol. 2015; 11: 181-4.
110. Cheng X, Bennett RL, Liu X, et al. PKR negatively regulates leukemia progression in association with PP2A activation, Bcl-2 inhibition and increased apoptosis. Blood Cancer J. 2013; 3: e144.
111. Shen Y, Wang X, Xia W, et al. Antiproliferative and overadditive effects of rapamycin and FTY720 in pancreatic cancer cells in vitro. Transplant Proc. 2008; 40: 1727-33.